Peter H. J. Slootbeek

Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy

Maarten J. van der Doelen, Niven Mehra, Inge M. van Oort et al. · Urologic Oncology Seminars and Original Investigations · 2021 · 79 citations · Full text

Medicine, Oncology, Urology +17

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

Maarten J. van der Doelen, Pedro Isaacsson Velho, Peter H. J. Slootbeek et al. · European Journal of Cancer · 2020 · 58 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Bastiaan M. Privé, Peter H. J. Slootbeek, Babette I. Laarhuis et al. · Prostate Cancer and Prostatic Diseases · 2021 · 41 citations · Full text

Medicine, Molecular Biology, Oncology +16

Impact of <scp>DNA</scp> damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer

Peter H. J. Slootbeek, Marleen L. Duizer, Maarten J. van der Doelen et al. · International Journal of Cancer · 2020 · 36 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer

Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits et al. · British Journal of Cancer · 2021 · 15 citations · Full text

Medicine, Molecular Medicine, Oncology +17